Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Three-dimensional imaging in myotonic dystrophy type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Koehorst, Emma
  • Linares-Pardo, Ian
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Guanyabens Busca, Nicolau|||0000-0002-2074-2744
  • Lopez-Osias, Marta
  • Suárez-Mesa, Adrián
  • Hanick, Shaliza Ann
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Nogales, Gisela|||0000-0002-7414-212X
We aimed to determine whether 3D imaging reconstruction allows identifying molecular:clinical associations in myotonic dystrophy type 1 (DM1). We obtained myoblasts from 6 patients with DM1 and 6 controls. We measured cytosine-thymine-guanine (CTG) expansion and detected RNA foci and muscleblind like 1 (MBNL1) through 3D reconstruction. We studied dystrophia myotonica protein kinase (DMPK) expression and splicing alterations of MBNL1, insulin receptor, and sarcoplasmic reticulum Ca(2+)-ATPase 1. Three-dimensional analysis showed that RNA foci (nuclear and/or cytoplasmic) were present in 45%-100% of DM1-derived myoblasts we studied (range: 0-6 foci per cell). RNA foci represented <0.6% of the total myoblast nuclear volume. CTG expansion size was associated with the number of RNA foci per myoblast (r = 0.876 [95% confidence interval 0.222-0.986]) as well as with the number of cytoplasmic RNA foci (r = 0.943 [0.559-0.994]). Although MBNL1 colocalized with RNA foci in all DM1 myoblast cell lines, colocalization only accounted for 1% of total MBNL1 expression, with the absence of DM1 alternative splicing patterns. The number of RNA foci was associated with DMPK expression (r = 0.967 [0.079-0.999]). On the other hand, the number of cytoplasmic RNA foci was correlated with the age at disease onset (r = -0.818 [-0.979 to 0.019]). CTG expansion size modulates RNA foci number in myoblasts derived from patients with DM1. MBNL1 sequestration plays only a minor role in the pathobiology of the disease in these cells. Higher number of cytoplasmic RNA foci is related to an early onset of the disease, a finding that should be corroborated in future studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation

  • Koehorst, Emma
  • Odria, Renato|||0000-0002-3420-797X
  • Capó, Júlia
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Arbex, Andrea|||0000-0002-3741-4755
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Linares-Pardo, Ian
  • Natera de Benito, Daniel
  • Saez, Verónica
  • Nascimento, Andrés
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Rubio, Miguel Ángel|||0000-0003-0735-6854
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
Myotonic dystrophy type 1 (DM1) is a progressive, non-treatable, multi-systemic disorder. To investigate the contribution of epigenetics to the complexity of DM1, we compared DNA methy-lation profiles of four annotated CpG islands (CpGis) in the DMPK locus and neighbouring genes, in distinct DM1 tissues and derived cells, representing six DM1 subtypes, by bisulphite sequencing. In blood, we found no differences in CpGi 74, 43 and 36 in DNA methylation profile. In contrast, a CTCF1 DNA methylation gradient was found with 100% methylation in congenital cases, 50% in childhood cases and 13% in juvenile cases. CTCF1 methylation correlated to disease severity and CTG expansion size. Notably, 50% of CTCF1 methylated cases showed methylation in the CTCF2 regions. Additionally, methylation was associated with maternal transmission. Interestingly, the evaluation of seven families showed that unmethylated mothers passed on an expansion of the CTG repeat, whereas the methylated mothers transmitted a contraction. The analysis of patient-derived cells showed that DNA methylation profiles were highly preserved, validating their use as faithful DM1 cellular models. Importantly, the comparison of DNA methylation levels of distinct DM1 tissues revealed a novel muscle-specific epigenetic signature with methylation of the CTCF1 region accompanied by demethylation of CpGi 43, a region containing an alternative DMPK promoter, which may decrease the canonical promoter activity. Altogether, our results showed a distinct DNA methylation profile across DM1 tissues and uncovered a novel and dual epigenetic signature in DM1 muscle samples, providing novel insights into the epigenetic changes associated with DM1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of Potential Muscle Biomarkers in McArdle Disease, Insights from Muscle Proteome Analysis

  • García-Consuegra, Inés
  • Asensio-Peña, Sara|||0000-0002-2048-5899
  • Garrido-Moraga, Rocío|||0000-0002-2856-4399
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Nogales, Gisela|||0000-0002-7414-212X
  • Serrano-Lorenzo, Pablo|||0000-0002-5661-7574
  • Andreu Périz, Antoni Lluís
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Zugaza, José L.|||0000-0002-9000-6398
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Martín, Miguel A.|||0000-0003-4741-772X
Glycogen storage disease type V (GSDV, McArdle disease) is a rare genetic myopathy caused by deficiency of the muscle isoform of glycogen phosphorylase (PYGM). This results in a block in the use of muscle glycogen as an energetic substrate, with subsequent exercise intolerance. The pathobiology of GSDV is still not fully understood, especially with regard to some features such as persistent muscle damage (i.e., even without prior exercise). We aimed at identifying potential muscle protein biomarkers of GSDV by analyzing the muscle proteome and the molecular networks associated with muscle dysfunction in these patients. Muscle biopsies from eight patients and eight healthy controls showing none of the features of McArdle disease, such as frequent contractures and persistent muscle damage, were studied by quantitative protein expression using isobaric tags for relative and absolute quantitation (iTRAQ) followed by artificial neuronal networks (ANNs) and topology analysis. Protein candidate validation was performed by Western blot. Several proteins predominantly involved in the process of muscle contraction and/or calcium homeostasis, such as myosin, sarcoplasmic/endoplasmic reticulum calcium ATPase 1, tropomyosin alpha-1 chain, troponin isoforms, and alpha-actinin-3, showed significantly lower expression levels in the muscle of GSDV patients. These proteins could be potential biomarkers of the persistent muscle damage in the absence of prior exertion reported in GSDV patients. Further studies are needed to elucidate the molecular mechanisms by which PYGM controls the expression of these proteins.